‘R2’ Herpes Vaccine Shows Promise

Research By David I. Bernstein, MD, MA

Post Date: November 9, 2020 | Publish Date: Nov. 6, 2020

→

This chart depicts the severity of acute disease (0–14 dpi) following intravaginal challenge with HSV-2. IM vaccination with gD+MPL/Alum is included as a positive control. The severity of the acute disease was quantified using a score-scale ranging from 0 to 4. Error bars are standard deviation.

A modified live virus vaccine against cold-sore producing herpes simplex virus type 1 (HSV-1) generated a powerful antibody response in animal models and demonstrated cross-protection against HSV-2, which leads to genital herpes.

Findings were published Nov. 6, 2020, in the journal npj Vaccines. David I. Bernstein, MD, MA, at Cincinnati Children’s was corresponding author for the study, which included collaborators from Northwestern University and the University of Nebraska-Lincoln.

Despite decades of work, no vaccine has yet succeeded against HSV-1 or HSV-2. Experts estimate that about 400 million people have HSV-2, which can flare up during times of stress throughout an infected person’s life. HSV infections can be especially serious among immunocompromised people and may contribute to Alzheimer’s disease or other forms of dementia.

There are several types of herpes vaccine under evaluation. This one is dubbed “R2” because it modifies a protein in region 2 of the virus’ capsid, a region crucial to helping the virus invade nerve cells.

“The R2 design offers another solution to the challenge of producing a virus that replicates in the periphery inducing a strong immune response without seeding the nervous system and establishing a latent infection,” the study authors state.

The researchers found that recurrent virus shedding was reduced by 33% to 64% in each of the R2 vaccinated groups whereas the gD2+MPL/Alum control group showed no benefit.

“This is of particular importance because recurrent virus shedding is the main means of HSV transmission,” the co-authors say.

 

 

 

Publication Information

Original Title:The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model
Published in:npj Vaccines
Publish date:Nov. 6, 2020

Read the Study

Research By

  • David I. Bernstein, MD, MA

    David I. Bernstein, MD, MA

    Director, Gamble Program and VTEU

    I am interested in vaccines for common infections that have significant impact on human health. Most of the vaccines I study are related to herpes viruses, rotavirus, norovirus and influenza.